Front Cardiovasc Med :慢性阻塞性肺疾病患者的流感疫苗接种和室性心律失常风险:一项基于人群的纵向研究

2021-11-05 刘少飞 MedSci原创

流感疫苗接种可以降低慢性阻塞性肺疾病 (COPD) 患者发生主要心脏事件的风险。研究发现疫苗可降低此类患者发生室性心律失常 (VA)的风险。

慢性阻塞性肺疾病 (COPD) 是一种全球性的健康负担,在过去 30 年中已从第六位上升到第三位最常见的死因。研究表明,血管疾病是 COPD 患者的主要死亡原因。因为 COPD 患者通常有类似的合并症,会增加患心血管疾病的风险,所以心力衰竭、心肌梗塞和心律失常的风险也会增加。虽然室上性心律失常是 COPD 心律失常患者最常见的心律失常形式,但室性心律失常 (VA) 的风险也很高。

此外,COPD 患者猝死的风险显着增加。在 COPD 急性加重期,最常见的心律失常类型是室性早搏。QT 离散度增加、自主神经功能、低氧血症和高碳酸血症是 COPD 患者易受 VA 影响的拟议机制。VA 也是 COPD 患者急性加重期死亡的可能危险因素。

流感是 COPD 患者常见且严重的病毒感染。它不仅会增加发生急性呼吸衰竭的风险,还会增加发生急性心血管事件的风险。接种流感疫苗后,心肌梗塞和心源性猝死的风险降低。然而,COPD 患者中流感疫苗接种与 VA 之间的关联仍不清楚。因此,该研究调查了现实世界中流感疫苗接种与 VA 发生之间的关联。

研究方法:

1995 年建立的健康保险计划为超过 98% 的台湾人口(超过 2300 万人)提供健康保险。NHI 研究数据库 (NHIRD) 由健康与福利数据科学中心维护,并已被早期研究广泛分析和验证。在台湾,50岁以上患有高危合并症(即糖尿病、慢性肝病、肝硬化、心血管疾病或慢性肺病)的成年人免费接种流感疫苗。

研究队列和研究设计:

新研究的患者在 2001 年 1 月 1 日至 2012 年 12 月 31 日期间被诊断为 COPD。之前已经验证了 ICD-9-CM 代码在 COPD 诊断中的关键预测价值。

研究结果:

在所有季节,在主要模型中接种一次疫苗后观察到 VA 发生的风险显着降低(aHR:0.58 [95% CI:0.36-0.93])。接种2-3次和4次以上的VA发生率无显着差异。在年龄在 55 至 74 岁之间的患者中,接种 1 次和 2 至 3 次疫苗后观察到的 VA 风险显着降低(aHR:0.13 [95% CI:0.04-0.40]、0.48 [95% CI:0.27- 0.85])。在没有中风、外周血管疾病、糖尿病和 CHA 2 DS 2 的患者中-VASc 评分为 2-3,在接种 1 次和 2-3 次疫苗后观察到 VA 发生的风险显着降低。在有哮喘病史的患者中,首次接种疫苗后观察到 VA 发生的风险显着降低(aHR:0.33 [95% CI:0.14–0.78])。在没有心力衰竭、缺血性心脏病、高血压、心绞痛和肾功能衰竭的患者中,首次接种疫苗后观察到发生 VA 的风险显着降低。

在流感季节、非流感季节和所有季节,COPD相关住院次数超过2次,接种1次、2次、3次或4次以上的VA发生风险无显着差异. 在所有季节中,观察到首次接种疫苗后没有 COPD 相关住院患者发生 VA 的风险较低。此外,在一次 COPD 相关入院的患者中,发生 VA 的风险较低与接种两次以上有关。

研究结论:

在这项包括台湾 18,658 名患者在内的基于人群的纵向队列研究中,这是第一项调查流感疫苗接种与 COPD 患者 VA 风险之间关联的研究。揭示了以下主要发现:

(1) 流感疫苗接种与 COPD 患者发生潜在致命性 VA 的风险显着降低相关,

(2) 不止一种疫苗接种时间与 VA 发生风险较低相关,尤其是在 CHA 2 DS 2 -VASc 评分相对较高的患者中

(3) 在没有中风、缺血性心脏病、外周血管疾病、糖尿病和心力衰竭病史的患者中,观察到首次接种疫苗后发生 VA 的风险较低。在接受 2 至 3 次疫苗接种后,除了心力衰竭和缺血性心脏病外,没有这些病史的患者发生 VA 的风险较低。流感疫苗接种可能与 55-74 岁 COPD 患者发生潜在致命性 VA 的风险较低有关。需要进一步的研究来解决这个临床问题。

 

文章出处:

Chen CC, Lin CH, Hao WR, Yeh JS, Chiang KH, Fang YA, Chiu CC, Yang TY, Wu YW, Liu JC. Influenza Vaccination and the Risk of Ventricular Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease: A Population-Based Longitudinal Study. Front Cardiovasc Med. 2021 Oct 14;8:731844. doi: 10.3389/fcvm.2021.731844. PMID: 34722665; PMCID: PMC8551488.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1721482, encodeId=3b4a1e21482ac, content=<a href='/topic/show?id=2db0e749190' target=_blank style='color:#2F92EE;'>#纵向研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77491, encryptionId=2db0e749190, topicName=纵向研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22a833008274, createdName=jj000012, createdTime=Thu Dec 09 14:22:43 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019524, encodeId=445f2019524c7, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Apr 26 01:22:43 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696989, encodeId=53371696989cf, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Sep 02 18:22:43 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939264, encodeId=59531939264e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 18 05:22:43 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799181, encodeId=47d21e9918125, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 28 10:22:43 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258113, encodeId=5a79125811304, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611319, encodeId=b59116113192a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1721482, encodeId=3b4a1e21482ac, content=<a href='/topic/show?id=2db0e749190' target=_blank style='color:#2F92EE;'>#纵向研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77491, encryptionId=2db0e749190, topicName=纵向研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22a833008274, createdName=jj000012, createdTime=Thu Dec 09 14:22:43 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019524, encodeId=445f2019524c7, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Apr 26 01:22:43 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696989, encodeId=53371696989cf, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Sep 02 18:22:43 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939264, encodeId=59531939264e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 18 05:22:43 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799181, encodeId=47d21e9918125, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 28 10:22:43 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258113, encodeId=5a79125811304, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611319, encodeId=b59116113192a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1721482, encodeId=3b4a1e21482ac, content=<a href='/topic/show?id=2db0e749190' target=_blank style='color:#2F92EE;'>#纵向研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77491, encryptionId=2db0e749190, topicName=纵向研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22a833008274, createdName=jj000012, createdTime=Thu Dec 09 14:22:43 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019524, encodeId=445f2019524c7, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Apr 26 01:22:43 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696989, encodeId=53371696989cf, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Sep 02 18:22:43 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939264, encodeId=59531939264e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 18 05:22:43 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799181, encodeId=47d21e9918125, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 28 10:22:43 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258113, encodeId=5a79125811304, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611319, encodeId=b59116113192a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-09-02 tomyang96
  4. [GetPortalCommentsPageByObjectIdResponse(id=1721482, encodeId=3b4a1e21482ac, content=<a href='/topic/show?id=2db0e749190' target=_blank style='color:#2F92EE;'>#纵向研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77491, encryptionId=2db0e749190, topicName=纵向研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22a833008274, createdName=jj000012, createdTime=Thu Dec 09 14:22:43 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019524, encodeId=445f2019524c7, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Apr 26 01:22:43 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696989, encodeId=53371696989cf, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Sep 02 18:22:43 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939264, encodeId=59531939264e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 18 05:22:43 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799181, encodeId=47d21e9918125, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 28 10:22:43 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258113, encodeId=5a79125811304, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611319, encodeId=b59116113192a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
    2022-04-18 quxin068
  5. [GetPortalCommentsPageByObjectIdResponse(id=1721482, encodeId=3b4a1e21482ac, content=<a href='/topic/show?id=2db0e749190' target=_blank style='color:#2F92EE;'>#纵向研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77491, encryptionId=2db0e749190, topicName=纵向研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22a833008274, createdName=jj000012, createdTime=Thu Dec 09 14:22:43 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019524, encodeId=445f2019524c7, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Apr 26 01:22:43 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696989, encodeId=53371696989cf, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Sep 02 18:22:43 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939264, encodeId=59531939264e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 18 05:22:43 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799181, encodeId=47d21e9918125, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 28 10:22:43 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258113, encodeId=5a79125811304, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611319, encodeId=b59116113192a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1721482, encodeId=3b4a1e21482ac, content=<a href='/topic/show?id=2db0e749190' target=_blank style='color:#2F92EE;'>#纵向研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77491, encryptionId=2db0e749190, topicName=纵向研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22a833008274, createdName=jj000012, createdTime=Thu Dec 09 14:22:43 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019524, encodeId=445f2019524c7, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Apr 26 01:22:43 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696989, encodeId=53371696989cf, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Sep 02 18:22:43 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939264, encodeId=59531939264e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 18 05:22:43 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799181, encodeId=47d21e9918125, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 28 10:22:43 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258113, encodeId=5a79125811304, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611319, encodeId=b59116113192a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1721482, encodeId=3b4a1e21482ac, content=<a href='/topic/show?id=2db0e749190' target=_blank style='color:#2F92EE;'>#纵向研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77491, encryptionId=2db0e749190, topicName=纵向研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22a833008274, createdName=jj000012, createdTime=Thu Dec 09 14:22:43 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019524, encodeId=445f2019524c7, content=<a href='/topic/show?id=dbba65336b1' target=_blank style='color:#2F92EE;'>#流感疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65336, encryptionId=dbba65336b1, topicName=流感疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Tue Apr 26 01:22:43 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696989, encodeId=53371696989cf, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Sep 02 18:22:43 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939264, encodeId=59531939264e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 18 05:22:43 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799181, encodeId=47d21e9918125, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 28 10:22:43 CST 2022, time=2022-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258113, encodeId=5a79125811304, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611319, encodeId=b59116113192a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 07 16:22:43 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

相关资讯

NEJM:单纯性夜间低氧慢阻肺患者的夜间氧疗是否有获益?

背景:长期氧气疗法可改善慢性阻塞性肺疾病(COPD)和慢性严重白天低氧血症患者的生存率。然而,氧疗法治疗孤立性夜间低氧血症的疗效尚不确定。

Eur Respir J:血液嗜酸性粒细胞计数和阻塞性肺疾病的关系

嗜酸性粒细胞计数与罹患OLD的风险呈正相关。该研究的结果表明,嗜酸性粒细胞计数可作为COPD发生发展的独立危险因素。

Eur Heart J:房颤患者慢性阻塞性肺疾病的患病率、治疗和影响

COPD在AF患者中很常见,13%的AF患者伴有COPD,并且与合并症负担增加、差异化管理和更差的结局相关,全因死亡风险增加两倍以上,此外大出血和心血管死亡风险增加。

Respiratory Research:透明质酸对治疗慢性肺部疾病有效

研究人员发现吸入透明质酸可改善慢性阻塞性肺疾病(COPD)严重加重患者的肺功能。透明质酸是一种由活组织分泌的糖,作为细胞的支架,也被用作化妆品的皮肤润肤霜和鼻腔喷雾,以滋润肺部呼吸道。

Radiology:多参数CT/MRI技术在慢性阻塞性肺疾病中的应用

慢性阻塞性肺疾病(COPD)的肺部影像学检查主要为CT或MRI,但尚无研究将两者一同评价。

AJRCCM:晚期肺动脉高压阻塞性肺功能的演变

肺动脉高压 (PAH) 的特征是肺动脉阻抗增加,导致运动不耐受和右心衰竭。 随着针对右心衰竭的治疗方法的改进,人们对 PAH 降低运动能力的新途径越来越感兴趣,这是一个关键的治疗目标。